ethylphenidate
Description
ethylphenidate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3080846 |
CHEMBL ID | 534479 |
CHEMBL ID | 1187932 |
SCHEMBL ID | 727938 |
MeSH ID | M0125225 |
Synonyms (14)
Synonym |
---|
57413-43-1 |
ethylphenidate |
bdbm50165211 |
phenyl-piperidin-2-yl-acetic acid ethyl ester; hydrochloride |
CHEMBL534479 , |
(2r,2''r)-phenyl-piperidin-2-yl-acetic acid ethyl ester; hydrochloride |
(2s,2''s)-phenyl-piperidin-2-yl-acetic acid ethyl ester; hydrochloride |
ethyl 2-phenyl-2-piperidin-2-ylacetate |
CHEMBL1187932 |
SCHEMBL727938 |
AKOS025149438 |
ethyl phenyl(piperidin-2-yl)acetate |
DTXSID60912317 |
Q5404506 |
Research Excerpts
Overview
Ethylphenidate is a new potent synthetic psychoactive drug, structurally related to methylphenidate. Methylphenidate (MPH) is a chiral compound with two chiral centers.
Pharmacokinetics
Methylphenidate concentrations were not markedly affected by ethanol. Ritalinic acid concentrations were lower, especially if ethanol was ingested first.
Bioavailability
This study explores the hypotheses that: (1) ethanol will interact with dl-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH. (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist.
Excerpt | Reference | Relevance |
---|---|---|
"This study explores the hypotheses that: (1) ethanol will interact with dl-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH, and primarily yield l-ethylphenidate as a transesterification metabolite; (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist." | ( Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. DeVane, CL; Herrin, AE; Janis, GC; Malcolm, R; Markowitz, JS; Minhinnett, RR; Patrick, KS; Straughn, AB; Yeatts, SD, 2007) | 0.84 |
" Specifically, we asked: (1) will ethanol increase d-MPH biological concentrations, (2) will MTS facilitate the systemic bioavailability of l-MPH, and (3) will l-MPH enantioselectively interact with ethanol to yield l-ethylphenidate (l-EPH)? Mice were dosed with MTS (¼ of a 12." | ( Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. Bell, GH; Griffin, WC; Novak, AJ; Patrick, KS, 2011) | 0.86 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Specifically, we asked: (1) will ethanol increase d-MPH biological concentrations, (2) will MTS facilitate the systemic bioavailability of l-MPH, and (3) will l-MPH enantioselectively interact with ethanol to yield l-ethylphenidate (l-EPH)? Mice were dosed with MTS (¼ of a 12." | ( Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. Bell, GH; Griffin, WC; Novak, AJ; Patrick, KS, 2011) | 0.86 |
" A marked individual variability in the dose-response has been observed, and therefore dosage must be titrated for optimal therapeutic effect with minimal toxicity." | ( Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects. Dinis-Oliveira, RJ, 2017) | 0.79 |
Research
Studies (30)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (3.33) | 18.7374 |
1990's | 1 (3.33) | 18.2507 |
2000's | 4 (13.33) | 29.6817 |
2010's | 21 (70.00) | 24.3611 |
2020's | 3 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 46.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.46) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (6.45%) | 5.53% |
Reviews | 3 (9.68%) | 6.00% |
Case Studies | 7 (22.58%) | 4.05% |
Observational | 1 (3.23%) | 0.25% |
Other | 18 (58.06%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |